Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday.
OXFD has been the topic of a number of other reports. ValuEngine downgraded shares of Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 1st. Piper Jaffray Companies restated an “overweight” rating on shares of Oxford Immunotec Global in a research report on Sunday, November 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $16.67.
Oxford Immunotec Global stock traded up $0.02 during trading hours on Thursday, reaching $14.90. 106,517 shares of the company’s stock traded hands, compared to its average volume of 104,300. Oxford Immunotec Global has a fifty-two week low of $10.00 and a fifty-two week high of $19.19. The company has a market cap of $387.25 million, a PE ratio of -10.96 and a beta of 0.11.
In other news, CEO Peter Wrighton-Smith sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $14.91, for a total value of $149,100.00. Following the completion of the sale, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $15.50, for a total value of $46,500.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at $139,500. The disclosure for this sale can be found here. Corporate insiders own 6.61% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in Oxford Immunotec Global by 45.8% during the 2nd quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock worth $424,000 after purchasing an additional 10,320 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Oxford Immunotec Global by 19.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 97,445 shares of the company’s stock worth $1,257,000 after purchasing an additional 16,070 shares in the last quarter. BlackRock Inc. increased its stake in Oxford Immunotec Global by 10.0% during the 2nd quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock worth $16,490,000 after purchasing an additional 116,814 shares in the last quarter. Citadel Advisors LLC bought a new stake in Oxford Immunotec Global during the 2nd quarter worth approximately $1,029,000. Finally, Renaissance Technologies LLC increased its stake in Oxford Immunotec Global by 84.7% during the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after purchasing an additional 9,658 shares in the last quarter. 90.94% of the stock is owned by institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Read More: Institutional Investors
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.